Ignite Creation Date:
2024-05-05 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00434291
Status:
COMPLETED
Last Update Posted:
2009-11-25
First Post:
2007-02-12
Brief Title:
Safety and Efficacy Comparison of TG-873870Nemonoxacin to Levofloxacin in Community-Acquired Pneumonia
Sponsor:
TaiGen Biotechnology Co Ltd
Organization:
TaiGen Biotechnology Co Ltd
Study Overview
Official Title:
A Randomized Double-Blind Comparative Multi-Center Study of the Safety and Efficacy of TG-873870Nemonoxacin Versus Levofloxacin in Adult Patients With Community-Acquired Pneumonia CAP
Status:
COMPLETED
Status Verified Date:
2009-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will test the safety and efficacy of TG-873870Nemonoxacin compared with Levofloxacin in adult patients with Community-Aquired PneumoniaCAP
Detailed Description:
Community-acquired PneumoniaCAP remains a leading cause of death in both developing and developed countries In the choice of antibacterial agents used to treat CAP fluoroquinolones have received considerable attention because of their wide spectrum of bactericidal activity TG-873870Nemonoxacin a non-fluorinated quinolone NFQ is a selective bacterial topoisomerase inhibitor This study will test the safety and efficacy of TG-873870Nemonoxacin compared with Levofloxacin in adult patients with Community-Aquired Pneumonia CAP
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None